Zacks Investment Research Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell

Zacks Investment Research lowered shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a hold rating to a sell rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald raised their price objective on shares of Corvus Pharmaceuticals from $5.00 to $8.00 and gave the stock an overweight rating in a research note on Friday, December 3rd. Jefferies Financial Group initiated coverage on shares of Corvus Pharmaceuticals in a research note on Wednesday, December 1st. They set a buy rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $5.55.

NASDAQ:CRVS opened at $2.25 on Tuesday. Corvus Pharmaceuticals has a 12 month low of $1.86 and a 12 month high of $9.54. The firm has a market cap of $104.73 million, a price-to-earnings ratio of 37.50 and a beta of 0.87. The company’s 50 day moving average is $3.03 and its 200-day moving average is $3.31.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Sunday, October 31st. The company reported ($0.24) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.24). As a group, research analysts expect that Corvus Pharmaceuticals will post -0.98 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the stock. Tang Capital Management LLC bought a new position in shares of Corvus Pharmaceuticals in the third quarter valued at about $18,147,000. BVF Inc. IL raised its holdings in shares of Corvus Pharmaceuticals by 13.9% in the second quarter. BVF Inc. IL now owns 3,678,626 shares of the company’s stock valued at $9,822,000 after buying an additional 449,200 shares during the last quarter. VR Adviser LLC bought a new position in shares of Corvus Pharmaceuticals in the third quarter valued at about $16,589,000. Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 10.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,109,218 shares of the company’s stock worth $2,962,000 after purchasing an additional 109,099 shares during the last quarter. Finally, Pura Vida Investments LLC bought a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $3,554,000. 77.05% of the stock is owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors.

Recommended Story: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.